Medical/Pharmaceuticals
111 to Announce Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on March 20, 2025 - Conference Call to Follow
SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that it will repor...
2025-02-20 18:00
3293
Hong Kong Pharma Digital Technology Holdings Limited Partners with Leading Chinese E-commerce Platform to Enhance Cross-Border Logistics Services
NEW YORK, Feb. 20, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited has recently signed a cooperation agreement with a leading technology-driven e-commerce platform serving hundreds of millions of consumers. This partnership aims to revolutionize cross-border logistics s...
2025-02-20 17:23
2927
Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, a...
2025-02-20 15:31
3101
Nona Biosciences Announces Licensing Agreement with the University of Alabama at Birmingham to Support B Cell Development Research
CAMBRIDGE, Mass., Feb. 19, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to I™), today announced a licensing agreement with theUniversity of Alabama at Birmingham (UAB) to support their research in B cell development. Und...
2025-02-20 09:21
2671
Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA
SYDNEY, Feb. 19, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce thatthe Un...
2025-02-19 22:09
3677
Brexogen and BMI Korea Enter Strategic Technology Transfer Agreement for Exosome Therapeutics
Out-licenses BxC-I17e, Exosome-Based Therapeutics for New Indications
KRW 3 Billion Non-Refundable Upfront Payment + Milestone Payments +
Double-Digit Percentage Royalties
SEOUL, South Korea, Feb. 19, 2025 /PRNewswire/ -- Brexogen
2025-02-19 21:00
2846
Biosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US
NEWARK, Del. and NANJING, China, Feb. 19, 2025 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical-stage biotechnology company, is pleased to announce the appointment ofKedan Lin, Ph.D., as Chief Development Officer and President of Biosion US. With over two decades of expertise in biote...
2025-02-19 19:39
5441
AESOP Technology Unveils World's First Machine Learning Model to Combat Wrong-Site Surgery
SAN FRANCISCO, Feb. 18, 2025 /PRNewswire/ -- Wrong-site surgery (WSS), a critical "Never Event," represents a failure that should never occur in healthcare. Yet, due to underreporting, the true prevalence of these incidents remains obscured, jeopardizing patient safety and healthcare management.A...
2025-02-19 00:30
2710
VIVOZON Pharmaceutical Obtains MFDS Approval for UNAFRA Inj.: A Breakthrough Non-Opioid analgesic
SEOUL, South Korea, Feb. 18, 2025 /PRNewswire/ -- On February 17, VIVOZON Pharmaceutical announced that its non-opioid analgesic, UNAFRA Inj., was approved onDecember 12, 2024. (active ingredient: Opiranserin HCl), has received approval from the Ministry of Food and Drug Safety (MFDS). With this ...
2025-02-18 23:35
2420
HIMIAO Unveils BhairCx3™ Shine Factor ---- A Breakthrough in Feline Fur Care
XI'AN, China, Feb. 18, 2025 /PRNewswire/ -- The number of cat owners has surged dramatically in recent years. According to the 2025 White Paper onChina's Pet Industry, the number of pet cats inChina surpassed 71.53 million in 2024, accounting for 57.6% of all pet-owning households. However, as ca...
2025-02-18 22:15
2340
Transformation and rapid development of Visionary through the business integration
TORONTO, Feb. 18, 2025 /PRNewswire/ -- On January 26, 2025, Visionary's 2024 Annual Conference was held inToronto, celebrating the successful listing of Visionary's Pegasus New Energy Vehicles, SBS Green Energy, UBX FinTech, and American Precision Biotech on the U.S. OTC market. 2024 is a year of...
2025-02-18 22:00
3438
AHG Utilizes DeepSeek to Advance AI in Healthcare
QINGDAO, China, Feb. 18, 2025 /PRNewswire/ -- Akso Health Group (NASDAQ: AHG) (hereinafter referred to as "Akso Health," "the Company," or "we") announced today its integration of DeepSeek's advanced artificial intelligence technology. This initiative aims to further enhance AI-powered medical c...
2025-02-18 21:30
2953
Fangzhou Inc. integrates DeepSeek open-source AI Model to enhance Internet healthcare
SHANGHAI, Feb. 18, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced the successful integration and local deployment of the DeepSeek-R1 open-source large language model onFebruary 8th. This upgrade is expected to yiel...
2025-02-18 21:16
2847
PharmaBlock Launches Commercial GMP Workshop 503 at Zhejiang Site
NANJING, China, Feb. 18, 2025 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE) has announced the official launch of its commercial GMP Workshop 503 (W503) at PharmaBlock Zhejiang. The new workshop significantly enhances production capacity and further refines the hi...
2025-02-18 19:52
3336
WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year
* Ranked among the top 1% of more than 150,000 companies across 185 countries * Trusted by global partners for strong sustainability commitment * Recognized as a leader in Green CRDMO, driving innovation for a healthier future SHANGHAI, Feb. 18, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio"...
2025-02-18 17:00
3427
CJ Bioscience to Present Preclinical Data on Inflammatory Bowel Disease Pipeline Candidate CJRB-201 at 'ECCO 2025'; Clinical Entry Targeted for 2026
* 'CJRB-201', a proprietary strain of Faecalibacterium with potent its anti-inflammatory effects, has demonstrated the strongest induction of regulatory T cells (Tregs) among analyzed strains. * Preclinical studies in multiple animal models confirm significant improvements in key disease indi...
2025-02-18 15:00
3228
Fosun Pharma Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation
SHANGHAI, Feb. 17, 2025 /PRNewswire/ -- Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the transforma...
2025-02-17 16:22
4008
IASO Bio Announces Acceptance of New Drug Application for Equecabtagene Autoleucel (FUCASO) by the Hong Kong Department of Health
SHANGHAI and NANJING, China and SAN JOSE, Calif., Feb. 14, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that theHong Kong ...
2025-02-14 22:30
5406
Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases
BOSTON, Feb. 14, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, today announced the successful completion of its oversubscribed Series A financing of approximately $90 million....
2025-02-14 21:56
4484
Kexing Biopharm Obtained IND Approval for Its Self-developed GB05 from U.S. FDA
SHENZHEN, China, Feb. 14, 2025 /PRNewswire/ -- Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05, Human Interferon α1b Inhalation Solution, a self-developed product by the Company's wholly-owned subsidiary, Shenzhen K...
2025-02-14 21:00
6733
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 292 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 281 media titles]
2026-10-15 10:00Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 280 media titles]
2026-10-15 12:59
DayOne Upsizes Malaysia Financing to US$7.2 Billion; Total Billings Surpass 1GW and Bookings Reach 2.3GW
[Picked up by 270 media titles]
2026-10-14 18:01Most Read
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
20178
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
2026-10-13 10:00
18172
Agoda and Emerging Travel Group Enter Strategic Partnership
2026-10-15 16:00
8438